RecruitingCarcinoma, Non-Small-Cell Lung

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Eligible age

18+ yrs

Accepts

All genders

Locations

30 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.

Sponsor: Eli Lilly and Company

You may qualify if…

✓ Histological or cytological confirmation of NSCLC.
✓ Part A
✓ 1. Clinical Stage II-IIIB (N2) treated with presurgical chemoimmunotherapy, with residual tumor present at time of surgery. Patients with a pathologic complete response are not eligible.
✓ 2. Pathologic Stage II-IIIB (N2) NSCLC treated with initial upfront resection.
✓ Part B - Clinical Stage III, unresectable NSCLC, without progression on concurrent platinum-based chemoradiotherapy.
✓ Must have disease with evidence of KRAS G12C mutation.
✓ Must have known programmed death-ligand 1 (PD-L1) expression
✓ Must have an ECOG performance status of 0 or 1.

You may not qualify if…

✕ Have known changes in the EGFR or ALK genes.
✕ Have another type of cancer that is progressing or required active treatment within the past 2 years before screening.
✕ Have an active autoimmune disease that required systemic treatment in the past 2 years. Endocrine replacement therapy is allowed.
✕ Had any immune-related side effect or allergic reaction (Grade 3 or higher) from a previous immunotherapy medicine, or any immune-related side effect greater than Grade 1 that has not resolved. This does not apply for people with hormone-related diseases who are now on stable hormone replacement therapy.